31 results on '"Ongaro E"'
Search Results
2. PO-1112: Total neoadjuvant therapy in high risk rectal cancer: a feasibility pilot study
3. 416P A novel prognostic tool based on lymphocyte ratios in patients with stage III colon cancer
4. P-246 Taxane cross-resistance: An exploratory analysis of second-line chemotherapy for metastatic gastric cancer
5. P-266 LDH levels as predictors of efficacy in second-line treatment for metastatic gastric cancer: The LINE study
6. PIK3CA mutation in metastatic colorectal cancer (mCRC): Association with clinico-pathological features and outcome
7. Drug holidays and overall survival in patients treated for metastatic colorectal cancer
8. The SAFFO study: Sex-related prognostic role and cut-oFf deFinition of monocyte-to-lymphocyte ratio (MLR) in metastatic colOrectal cancer
9. SUN-PO094: The Role of Nutritional Interventions in Surgically Treated Pancreatic Cancer Patients: Comparative Efficacy in a Network Meta-Analysis (NMA)
10. The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA)
11. Monocyte-to-lymphocye ratio (MLR) and LDH level in metastatic colorectal cancer (mCRC) patients (pts)
12. The SENECA study: Prognostic role of serum biomarkers in elderly metastatic colorectal cancer patients
13. Determinants of oncologist’s choice in offering drug holidays during first line therapy for patients with metastatic colorectal cancer
14. The SLICE study: The prognostic role of visceral fat in metastatic colorectal cancer
15. Molecular characterization of immune microenvironment in colorectal cancers with microsatellite instability by digital RNA counting
16. Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liver-limited metastatic colorectal cancer (mCRC)
17. How can molecular heterogeneity impact on treatment choice in advanced colorectal cancer?
18. Blood stream infection in cancer patients—device management and epidemiology: the BSIDE study
19. Mutational status and metastatic patteRn in a cohort Of ADvanced colorectal cancer patients: the ROAD study
20. Early loss of skeletal muscle mass (LSMM) as prognostic factor in metastatic pancreatic cancer (PC) patients
21. Mutational status and metastatic patteRn in a cohort Of ADvanced colorectal cancer (aCRC) patients (pts): The ROAD study
22. HER2 loss in HER2‐positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research
23. May mutational status influence the metastatic pattern of colorectal cancer patients?
24. Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer
25. KRAS status and risk of venous thromboembolic events in patients with metastatic colorectal cancer: a case-control study
26. Prognostic significance of KRAS mutation rate in metastatic colorectal cancer patients
27. Glucose metabolism enzymes gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer (CRC)
28. Pattern of metastasis and outcome in patients with colorectal cancer
29. Molecular profile of brain metastases from colorectal cancer and concordance with matched primary tumors
30. 2153 Analysis ofthe molecular profile of brain metastases from colorectal cancer and concordance with matched primary tumors
31. 2027 KRAS status and risk of venous thromboembolic events in patients with metastatic colorectal cancer: A case-control study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.